BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients lowsphincters pressure

Journal of Physiology and Pharmacology

Volumn 62, Issue 5, 2011, Pages 527-534

  Petrovic, I ^a   Dobric, I ^a   Drmic, D ^a   Sever, M ^a   Klicek, R ^a   Radic, B ^a   Brcic, L ^a   Kolenc, D ^a   Zlatar, M ^a   Kunjko, K ^a   Jurcic, D ^a   Martinac, M ^a   Rasic, Z ^a   Blagaic, A Boban ^a   Romic, Z ^a   Seiwerth, S ^a   Sikiric, P ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Acute pancreatitis; Esophagitis; Pancreatitis; Pentadecapeptide BPC 157; Sphincters failure

Indexed keywords

GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE;

ACUTE PANCREATITIS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUSAL ATTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; ESOPHAGITIS; ESOPHAGUS MANOMETRY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRESSURE MEASUREMENT; RAT;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; ANTI-ULCER AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGITIS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MANOMETRY; MIDDLE AGED; PANCREATITIS; PEPTIDE FRAGMENTS; PRESSURE; PROTEINS; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84855720398     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Sikiric P, Seiwerth S, Grabarevic Z, et al. Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Dig Dis Sci 1996; 41: 1518-1526.
2. Wang GJ, Gao CF, Wei D, Wang C, Ding SQ. Acute pancreatitis: etiology and common pathogenesis. World J Gastroenterol 2009; 15: 1427-1430.
3. Dobric I, Drvis P, Petrovic I, et al. title typecontributorProlonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157/title. J Pharmacol Sci 2007; 104: 7-18.
4. Petrovic I, Dobric I, Drvis P, et al. An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157. J Pharmacol Sci 2006; 102: 269-277.
5. Lambert R. Relative importance of biliary and pancreatic secretions in the genesis of esophagitis in rats. Am J Dig Dis 1962; 7: 1026-1033.
6. Naito Y, Uchiyama K, Kuroda M, et al. Role of pancreatic trypsin in chronic esophagitis induced by gastroduodenal reflux in rats. J Gastroenterol 2006; 41: 198-208.
7. Sikiric P, Seiwerth S, Brcic L, et al. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Curr Pharm Des 2010; 16: 1224-1234.
8. Davila M, Bresalier RS. Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 682-696.
9. Sikiric P, Jadrijevic S, Seiwerth S, et al. Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats. J Physiol (Paris) 1999; 93: 467-477.
10. Jurcic D, Bilic A, Schwarz D, et al. Lower gastrointestinal disorders in patients with irritable bowel syndrome. Coll Antropol 2008; 32: 755-759.
11. Bilic A, Jurcic D, Schwarz D, et al. Impaired esophageal function in patients with irritable bowel syndrome. Coll Antropol 2008; 32: 747-753.
12. Sikiric P, Seiwerth S, Grabarevic Z, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol (Paris) 1997; 91: 113-122.
13. Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A. BPC-15 reduces trinitrobenzene sulfonic acidinduced colonic damage in rats. J Pharmacol Exp Ther 1995; 272: 417-422.
14. Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm Res 2008; 57: 205-210.
15. Sikiric P, Seiwerth S, Grabarevic Z, et al. Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Dig Dis Sci 1996; 41: 1604-1614.
16. Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regul Pept 2010; 160: 26-32.
17. Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept 2010; 160: 33-41.
18. Jandric I, Vrcic H, Jandric Balen M, et al. Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incotinence models in female rats. J Physiol Pharmacol 2009; 60(Suppl 2): 41.
19. Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today 2007; 37: 768-777.
20. Sever M, Klicek R, Radic B, et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci 2009; 54: 2070-2083.
21. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res 2006; 24: 1109-1117.
22. Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit 2010; 16: BR81-BR88.
23. Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today 2008; 38: 716-725.
24. Boban Blagaic A, Blagaic V, Mirt M, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol 2005; 512: 173-179.
25. Tohyama Y, Sikiric P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements. Life Sci 2004; 76: 345-357.
26. Jelovac N, Sikiric P, Rucman R, et al. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol 1999; 379: 19-31.
27. Jelovac N, Sikiric P, Rucman R, et al. A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biol Psychiatry 1998; 43: 511-519.
28. Sikiric P, Marovic A, Matoz W, et al. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. J Physiol (Paris) 1999; 93: 505-512.
29. Balenovic D, Bencic ML, Udovicic M, et al. Inhibition of methyldigoxin-induced arrhythmias by pentadecapeptide BPC 157: a relation with NO-system. Regul Pept 2009; 156: 83-89.
30. Klicek R, Sever M, Radic B, et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. J Pharmacol Sci 2008; 108: 7-17.
31. Boban-Blagaic A, Blagaic V, Romic Z, et al. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. The effect of N (G)-nitro-Larginine methyl ester and L-arginine. Med Sci Monit 2006; 12: BR36-BR45.
32. Sikiric P, Seiwerth S, Grabarevic Z, et al. The influence of a novel pentadecapeptide, BPC 157, on N (G)-nitro-Larginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997; 332: 23-33.
33. Grabarevic Z, Tisljar M, Artukovic B, et al. The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. J Physiol (Paris) 1997; 91: 139-149.
34. Lovric-Bencic M, Sikiric P, Hanzevacki JS, et al. Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. J Pharmacol Sci 2004; 95: 19-26.
35. Turkovic B, Sikiric P, Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157 studied forinflammatory bowel disease (PLD-116, PL14736, Pliva) induces nitric oxide synthesis. Gastroenterology 2004; 126: 287.
36. Orsolic N, Seiwerth S, Sikiric P. BPC 157 enhances function of immunological effector cells in mice. J Physiol Pharmacol 2009; 60(Suppl 2): 69.
37. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994; 343: 1199-1209.
38. Tomita R, Tanjoh K, Fujisaki S, Fukuzawa M. Physiological studies on nitric oxide in the lower esophageal sphincter of patients with reflux esophagitis. Hepatogastroenterology 2003; 50: 110-114.
39. DeValult K, Rattan S. Physiological role of neuropeptides in gastrointestinal smooth muscle sphincters: neuropeptide and VIF-nitric oxide interaction. In Gut Peptides: Biochemistry and Physiology, JH Walsh, GJ Dockray (eds). New York, Raven Press Ltd., 1994, pp. 715-747.
40. Holzer P. Capsaicin: cellular targets, mechanisms of action and selectivity for thin sensory neurons. Pharmacol Rev 1991; 43: 143-201.
41. Jaworek J, Jachimczak B, Bonior J, et al. Protective role of endogenous nitric oxide (NO) in lipopolysaccharide-induced pancreatic damage (a new experimental model of acute pancreatitis). J Physiol Pharmacol 2000; 51: 85-102.
42. Zaninotto G, DeMeester TR, Schwizer W, Johansson KE, Cheng SC. The lower esophageal sphincter in health and disease. Am J Surg 1988; 155: 104-110.
43. Jenkinson LR, Ball CS, Barlow AP, et al. A re-evaluation of the manometric assessment of oesophageal function in reflux oesophagitis. Gullet 1991; 1: 135-142.
44. Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut 2001; 49: 145-151.